BWBBP
Bridgewater Bancshares Inc
$19.85
0.00%
$553.5M
No data for this timeframe.
Vol
Market Cap$553.5M
Cap SizeSmall Cap
SEC Reports2
Recent Activity
May 19, 2026
clinical_trial_readout
T-90d Trial Readout: BBT-207 (Phase 2)
Trial: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutatio
May 4, 2026
SEC
Bridgewater Bancshares filed an 8-K with an investor presentation as of May 4, 2026, detailing Q1 2026 financial highlig
8-K — Impact 3/10
Apr 21, 2026
SEC
Bridgewater Bancshares reported strong first quarter 2026 results with net income of $17.4 million ($0.58 diluted EPS),
8-K — Impact 7/10
Analyst Ratings
1Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 75% buy across 8 analysts — 1 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 21.9% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 20.2% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 21.3% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 11.9% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
Clinical Trial
First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Phase Phase 2 — ACTIVE_NOT_RECRUITING
May 19, 2026
clinical_trial_readout
T-90d Trial Readout: BBT-207 (Phase 2)
Trial: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Sponsor: Bridge Bi
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: BBT-207 (Phase 2)
Trial: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Sponsor: Bridge Bi